Brief: Fate Therapeutics Highlights Positive Interim Data From Phase 1 Study Of Ft516 For B-Cell Lymphoma

Fate Therapeutics

04/06/2021 12:15

June 4 (Reuters) - Fate Therapeutics Inc  FATE.O :
    * FATE THERAPEUTICS HIGHLIGHTS POSITIVE INTERIM DATA FROM
ITS
PHASE 1 STUDY OF FT516 IN COMBINATION WITH RITUXIMAB FOR B-CELL
LYMPHOMA AT 2021 ASCO ANNUAL MEETING
    * FATE THERAPEUTICS INC - 8 OF 11 PATIENTS IN DOSE
ESCALATION
COHORTS 2 AND 3 ACHIEVED OBJECTIVE RESPONSE
    * FATE THERAPEUTICS INC - 6 OF 11 PATIENTS ACHIEVED COMPLETE
RESPONSE, INCLUDING 2 PATIENTS PREVIOUSLY TREATED WITH
AUTOLOGOUS CD19 CAR T-CELL THERAPY
    * FATE THERAPEUTICS INC - FAVORABLE FT516 SAFETY PROFILE WAS
OBSERVED IN PHASE 1 STUDY
    * FATE THERAPEUTICS INC - NO FT516-RELATED SERIOUS ADVERSE
EVENTS
OR FT516-RELATED GRADE 3 OR GREATER ADVERSE EVENTS IN PHASE 1
STUDY

Source text for Eikon:  ID:nGNX9Mcz89 
Further company coverage:  FATE.O 

 ((Reuters.Briefs@thomsonreuters.com;))